A carregar...
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
PURPOSE: Modulation of vascular endothelial growth factor–mediated immune suppression via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We report results from the dose-finding and initial phase II expansion of a phase Ib/II study of lenvatinib plus pembrolizumab i...
Na minha lista:
| Publicado no: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7145588/ https://ncbi.nlm.nih.gov/pubmed/31961766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01598 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|